Skip to main content
. 2019 Jun 5;10:639. doi: 10.3389/fphar.2019.00639

Figure 1.

Figure 1

The effects of KR-12-a5 on viability of HBMSCs. (A) HBMSCs were treated with different concentrations of KR-12-a5 for 1, 3, and 5 days prior to measuring the cell viability by a CCK-8 test. (B, C) Cell cycle and cell apoptosis were carried out by flow cytometry after 48-h incubation with different concentrations of KR-12-a5.